HelperbyTherapeutics

Biopharmaceutical company dedicated to outsmarting highly antibiotic resistant bacteria by developing the next generation of lifesaving antibiotics

[HelperbyTherapeutics @Helperby_Future]

Helperby Therapeutics has developed the quicker, safer, and cheaper way to beat AMR. Read the full article @PMLivecom

[HelperbyTherapeutics @Helperby_Future]

@SepsisUK Dear Dr Davies

You were great on the BBC this morning.

One day, will we have effective antibiotics for Sepsis?

Maybe, if we recycle combinations of old antibiotics.

Would you like to discuss?

Prof Anthony Coates

[HelperbyTherapeutics @Helperby_Future]

“By contrast, combination therapy – using more than one complementary drug in concert – is standard in many other fields. “Aids is one, oncology is another,” he says. “Why aren’t we doing this with common bacteria?”” https://t.co/ajaA0csYaJ

[HelperbyTherapeutics @Helperby_Future]

Our renewable antibiotic pipeline has several therapies in clinical trials across areas of significant market value. #Biotech #Biotechinvestor https://t.co/yUyl2rm0b3

[HelperbyTherapeutics @Helperby_Future]

We have a pipeline of solutions to the #AntibioticCrisis which are just 3-5 years from market. Solutions to treat resistant infections now, and potentially safeguard our future https://t.co/9lbsJtupGd

[HelperbyTherapeutics @Helperby_Future]

We need new #antibiotics and we need to use them better to #StopSuperbugs and create a long-term #sustainable and cost-effective solution https://t.co/FtU90Pxlij

[The Pharmaceutical Marketing Group @PharmaMKTnet]

Helperby Therapeutics and UCLA to Collaborate on New Fast Track Antibiotic Therapies Aiming to Bring New Sophisticated Combination Therapies to Market in a Much-Reduced Timescale https://t.co/NepxLn3uqV

[Latest News from Business Wire @NewsFromBW]

Helperby Therapeutics and UCLA to Collaborate on New Fast Track Antibiotic Therapies Aiming to Bring New Sophisticated Combination Therapies to Market in a Much-Reduced Timescale https://t.co/B5yiruwwFo

[HelperbyTherapeutics @Helperby_Future]

Our R&D strategy is to use our proprietary #AntibioticResistance Breakers to boost the efficacy of existing, resistant, antibiotics. How does it work?... https://t.co/QGXme6espb

[HelperbyTherapeutics @Helperby_Future]

Helperby Therapeutics & Dr Pamela Yeh's team at UCLA to collaborate on new fast track antibiotic therapies to bring sophisticated combination therapies to market in a much-reduced timescale #AAW2018 #antibiotics #PRrequest

https://t.co/WwmScH8X3J
https://t.co/9FxOd0grLz

[HelperbyTherapeutics @Helperby_Future]

Helperby Therapeutics is to announce some exciting news tomorrow to coincide with WHO's antibiotic awareness week #AAW2018 #antibiotics #PRrequest

[HelperbyTherapeutics @Helperby_Future]

Such positive feedback for our candidate therapies at International Conference on Infectious Diseases 2018 Berlin. #ICID2018 #AMR #AntimicrobialResistance #AAW2018
https://t.co/QMQG4F6akQ

[HelperbyTherapeutics @Helperby_Future]

#ICID2018 Helperby Therapeutics' new class of ARB antibiotic therapy is one of only a handful of drug candidates that @WHO has identified as in development to tackle all 3 WHO Critical Priority pathogens; CRE/CRAB/CRPA #Antimicrobialresistance #AAW2018
https://t.co/RPchOdawZT

[HelperbyTherapeutics @Helperby_Future]

The biggest threats to #AntibioticResistance are #CRE, CRAB and #CRPA, and we're developing a combination therapy to tackle all 3 https://t.co/Krti86UuG1

[HelperbyTherapeutics @Helperby_Future]

ICID 2018, Berlin: Latest data on effect of azidothymidine with colistin combination antibiotic therapy in human presented by Kurt G. Naber, Technical University of Munich, Germany on behalf of Helperby Therapeutics. #ICID2018 #AMR #AAW2018
https://t.co/zVTkaq7E8r

[HelperbyTherapeutics @Helperby_Future]

Helperby Therapeutics’ research team lead symposium on novel antibiotics and their development for the treatment of highly resistant Gram-negative bacteria at ICID 2018. #ICID2018 #AMR #Antimicrobial resistance #AAW2018
https://t.co/rS914EulgW

[HelperbyTherapeutics @Helperby_Future]

International Conference on Infectious Diseases 2018 Berlin: Helperby Therapeutics to present alongside our research partners on our lead candidate antibiotic therapy azidothymidine in combination with colistin #ICID2018 #Antimicrobialresistance #AAW2018
https://t.co/Cd37TCNpJb

[HelperbyTherapeutics @Helperby_Future]

Helperby Therapeutics has developed a strong candidate for antibiotic therapy effective against multiple drug- resistant infections. We’ll be discussing this at ICID Berlin on 5th Nov #ICID 2018 #AMR #Antimicrobialresistance #AAW2018
https://t.co/jXtr3r0m87

[HelperbyTherapeutics @Helperby_Future]

Our patented Antibiotic Resistance Breaker #biotechnology works in combination with existing antibiotics, and aims to create a sustainable and commercially viable solution in high value markets. Learn more about Helperby's award-winning solution: https://t.co/yUyl2rm0b3